[Second-line treatment using novel chemotherapeutic and biologic agents].
The goal of therapy for recurrent cancer is to delay progression, relieve symptoms, and improve QOL. Cytotoxic agents combined with carboplatin for sensitive disease(TFIB6 months), and cytotoxic agents without cross-resistance to taxane/platinum against resistant diseases are required. There is a limit to improvement in efficacy by using cytotoxic agents, and a promising biological agent is expected to emerge while phase II studies of various biological agents continue. Regarding molecular-target drugs, only bevacizumab is confirmed to be effective at present, so it is used in monotherapy or combination therapy with anticancer drugs. In the GOG started a RCT of bevacizumab or placebo that was combined with TC regimen. Also in patients with chemo-sensitive disease, a RCT of TC regimen combined with or without bevacizumab started. In addition, EORTC and ICON trials of cediranib and erlotinib combined with platinum-based regimen are on-going.
Sugiyama
Toru
T
Dept. of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Morioka, Japan.
D000970:Antineoplastic Agents / Q000276:immunology / Q000592:standards / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D012008:Recurrence; D015996:Survival Rate
D000970:Antineoplastic Agents